AlphaTON Capital (NASDAQ: ATON) announced Nasdaq publicly congratulated the company for pioneering a blockchain-based cancer research tokenization initiative; the recognition was displayed on the Nasdaq Tower in Times Square on October 10, 2025. AlphaTON is partnering with Cyncado Therapeutics to fund oncology programs via tokenized assets, aiming to increase liquidity, improve transparency of fund allocation, lower investor minimums, and accelerate R&D timelines. The company said the model helped advance multiple research programs and that it plans to expand tokenization to more therapeutic areas and institutional partners.
AlphaTON Capital (NASDAQ: ATON) ha annunciato che Nasdaq ha pubblicamente elogiato l’azienda per aver aperto la strada a una iniziativa di tokenizzazione della ricerca sul cancro basata su blockchain; il riconoscimento è stato…
